Tyvaso (Treprostinil) for Pulmonary Hypertension | myPHteam

Connect with others who understand.

sign up Log in
About myPHteam
Powered By

Tyvaso is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to improve exercise capacity in cases of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease. Tyvaso may be referred to by its drug name, treprostinil.

Tyvaso is a prostaglandin. Prostaglandins are hormone-like compounds made by the body. Lower levels of prostaglandins are associated with narrowing of blood vessels in the lungs. Prostaglandins are believed to work in two ways. First, prostaglandins dilate the blood vessels of the lungs, increasing the blood flow and the amount of oxygen the cells receive. Second, prostaglandins help slow scarring in the blood vessels of the lungs, delaying the progress of the disease.

How do I take it?
Prescribing information states that Tyvaso is taken four times a day by inhalation.

Tyvaso comes in the form of ampules administered via the specialized Tyvaso inhalation system. The inhalation system must be newly assembled each day.

Side effects
The FDA-approved label for Tyvaso lists common side effects including headache, dizziness, sore throat, cough, flushed skin, and diarrhea.

Rare but serious side effects listed for Tyvaso include hypotension (low blood pressure), bleeding, and liver or kidney problems.

For more details about this treatment, visit:

Tyvaso — United Therapeutics

Continue with Facebook
Continue with Google
Lock Icon Your privacy is our priority. By continuing, you accept our Terms of use, and our Health Data and Privacy policies.
Already a Member? Log in